404 related articles for article (PubMed ID: 29345842)
1. Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
Amatatsu M; Arigami T; Uenosono Y; Yanagita S; Uchikado Y; Kijima Y; Kurahara H; Kita Y; Mori S; Sasaki K; Omoto I; Maemura K; Ishigami S; Natsugoe S
Cancer Sci; 2018 Mar; 109(3):814-820. PubMed ID: 29345842
[TBL] [Abstract][Full Text] [Related]
2. Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer.
Ubukata Y; Ogata K; Sohda M; Yokobori T; Shimoda Y; Handa T; Nakazawa N; Kimura A; Kogure N; Sano A; Sakai M; Ogawa H; Kuwano H; Shirabe K; Oyama T; Saeki H
Oncology; 2021; 99(1):15-22. PubMed ID: 33113541
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.
Ito S; Fukagawa T; Noda M; Hu Q; Nambara S; Shimizu D; Kuroda Y; Eguchi H; Masuda T; Sato T; Katai H; Sasako M; Mimori K
Ann Surg Oncol; 2018 Nov; 25(12):3755-3763. PubMed ID: 30203407
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
[TBL] [Abstract][Full Text] [Related]
10. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
11. Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
Oki E; Okano S; Saeki H; Umemoto Y; Teraishi K; Nakaji Y; Ando K; Zaitsu Y; Yamashita N; Sugiyama M; Nakashima Y; Ohgaki K; Oda Y; Maehara Y
Oncology; 2017; 93(6):387-394. PubMed ID: 28910818
[TBL] [Abstract][Full Text] [Related]
12. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
13. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
Ando K; Hamada K; Watanabe M; Ohkuma R; Shida M; Onoue R; Kubota Y; Matsui H; Ishiguro T; Hirasawa Y; Ariizumi H; Tsurutani J; Yoshimura K; Tsunoda T; Kobayashi S; Wada S
Anticancer Res; 2019 Sep; 39(9):5195-5201. PubMed ID: 31519633
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.
Eto S; Yoshikawa K; Nishi M; Higashijima J; Tokunaga T; Nakao T; Kashihara H; Takasu C; Iwata T; Shimada M
Gastric Cancer; 2016 Apr; 19(2):466-471. PubMed ID: 26210691
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
Yuan J; Zhang J; Zhu Y; Li N; Tian T; Li Y; Li Y; Li Z; Lai Y; Gao J; Shen L
Oncotarget; 2016 Jun; 7(26):39671-39679. PubMed ID: 27191996
[TBL] [Abstract][Full Text] [Related]
16. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
[No Abstract] [Full Text] [Related]
17. [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
Liu Y; Wang JF; Li XW; Bu P; Bai W; Li LM
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):597-602. PubMed ID: 30107664
[No Abstract] [Full Text] [Related]
18. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
19. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
20. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]